Missing CD4+ cell response in randomized clinical trials of maraviroc and dolutegravir

References

• Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ. 1999;319(7211):670–674.
   PubMed Web of Science ®Google Scholar
• Raboud JM, Montaner JS, Thorne A, Singer J, Schechter MT. Impact of missing data due to dropouts on estimates of the treatment effect in a randomized trial of antiretroviral therapy for HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;12(1):46–55.
   PubMedGoogle Scholar
• O'Neill RT, Temple R. The prevention and treatment of missing data in clinical trials: an FDA perspective on the importance of dealing with it. Clin Pharmacol Ther. 2012;91(3):550–554.
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation. E9: Statistical Principles for Clinical Trials (CPMP/ICH/363/96). 1998. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf.
   Google Scholar
• International Conference on Harmonisation. E10: Choice of Control Group and Related Issues in Clinical Trials. 2001. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E10/Step4/E10_Guideline.pdf..
   Google Scholar
• The Prevention and Treatment of Missing Data in Clinical Trials. Washington, DC: The National Academies Press; 2010.
   Google Scholar
• Ware JH, Harrington D, Hunter DJ, D'Agostino RB. Missing data. N Engl J Med. 2012;367(14):1353–1354.
   Web of Science ®Google Scholar
• Little RJ, D'Agostino R, Cohen ML, Dickersin K, Emerson SS, Farrar JT, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367(14):1355–1360.
   PubMed Web of Science ®Google Scholar
• Little RJ, Cohen ML, Dickersin K, Emerson SS, Farrar JT, Neaton JD, et al. The design and conduct of clinical trials to limit missing data. Stat Med. 2012;31(28):3433–3443.
   PubMed Web of Science ®Google Scholar
• Committee for Medical Products for Human Use. Guideline on Missing Data in Confirmatory Clinical Trials (EMA/CPMP/EWP/1776/99 Rev. 1) 2010.; http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/09/WC500096793.pdf.
   Google Scholar
• Abraham WT, Russell DW. Missing data: a review of current methods and applications in epidemiological research. Curr Opin Psychiatry. 2004;17(4):315–321.
   Web of Science ®Google Scholar
• Newgard CD, Haukoos JS. Advanced statistics: missing data in clinical research – part 2: multiple imputation. Acad Emerg Med. 2007;14(7):669–678.
   PubMed Web of Science ®Google Scholar
• Hughes S, Harris J, Flack N, Cuffe RL. The statistician's role in the prevention of missing data. Pharm Stat. 2012;11(5):410–416.
   PubMed Web of Science ®Google Scholar
• Harris J, Bomar M, Campbell M. Increasing subject compliance in pivotal phase III clinical trials of dolutegravir (DTG, S/GSK1349572) in HIV-infected, ART-naive subjects. J Int AIDS Soc. 2012;15(Suppl 4):1824
   Google Scholar
• Food and Drug Administration. Guidance for Industry: Antiretroviral Drugs Using Plasma HIV RNA Measurements – Clinical Considerations for Accelerated and Traditional Approval 2002.; http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm070968.pdf..
   Google Scholar
• Food and Drug Administration. Draft Guidance for Industry: Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment 2013.; http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm355128.pdf..
   Google Scholar
• Cohen CJ, Molina JM, Cahn P, Clotet B, Fourie J, Grinsztejn B, et al. Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE trials. J Acquir Immune Defic Syndr. 2012;60(1):33.
   PubMed Web of Science ®Google Scholar
• DeJesus E, Rockstroh JK, Henry K, Molina JM, Gathe J, Ramanathan S, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet. 2012;379(9835):2429–2438.
   PubMed Web of Science ®Google Scholar
• Sax PE, DeJesus E, Mills A, Zolopa A, Cohen C, Wohl D, et al. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks. Lancet. 2012;379(9835):2439–2448.
   PubMed Web of Science ®Google Scholar
• Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, et al. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013;381(9868):735–743.
   PubMed Web of Science ®Google Scholar
• Lennox JL, DeJesus E, Lazzarin A, Pollard RB, Madruga JV, Berger DS, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374(9692):796–806.
   PubMed Web of Science ®Google Scholar
• Bell ML, Fiero M, Horton NJ, Hsu CH. Handling missing data in RCTs; a review of the top medical journals. BMC Med Res Methodol. 2014;14:118.
   PubMed Web of Science ®Google Scholar
• Walmsley SL, Antela A, Clumeck N, Duiculescu D, Eberhard A, Gutiérrez F, et al. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection. N Engl J Med. 2013;369(19):1807–1818.
   PubMed Web of Science ®Google Scholar
• Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, Horban A, et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med. 2008;359(14):1429–1441.
   PubMed Web of Science ®Google Scholar
• Asmuth DM, Goodrich J, Cooper DA, Haubrich R, Rajicic N, Hirschel B, et al. CD4+T-cell restoration after 48 weeks in the maraviroc treatment-experienced trials MOTIVATE 1 and 2. J Acquir Immune Defic Syndr. 2010;54(4):394–397.
   PubMed Web of Science ®Google Scholar
• Mallinckrodt CH, Clark WS, Carroll RJ, Molenberghs G. Assessing response profiles from incomplete longitudinal clinical trial data under regulatory considerations. J Biopharm Stat. 2003;13(2):179–190.
   PubMedGoogle Scholar
• DART Trial Team. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts <  200 cells/microl. AIDS. 2008;22(2):237–247.
   PubMed Web of Science ®Google Scholar
• Strategies for Management of Antiretroviral Therapy (SMART) Study Group, El-Sadr WM, Lundgren J, Neaton JD, Gordin F, Abrams D, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283–2296.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Airoldi M, Callegaro A, Martinelli C, Dolara A, Bini T, et al. CD4 cell-guided scheduled treatment interruptions in HIV-infected patients with sustained immunologic response to HAART. AIDS. 2009;23(7):799–807.
   PubMed Web of Science ®Google Scholar
• Little RJ, Rubin DB. Statistical Inference with Missing Data. 2nd edn. New York: Wiley; 2002.
   Google Scholar
• Hogan JW, Roy J, Korkontzelou C. Handling drop-out in longitudinal studies. Stat Med. 2004;23(9):1455–1497.
   PubMed Web of Science ®Google Scholar
• Rubin DB. Inference and missing data. Biometrika. 1976;63(3):581–592.
   Web of Science ®Google Scholar
• Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med. 2008;359(4):339–354.
   PubMed Web of Science ®Google Scholar
• Katlama C, Haubrich R, Lalezari J, Lazzarin A, Madruga JV, Molina JM, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS. 2009;23(17):2289–2300.
   PubMed Web of Science ®Google Scholar